Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment

Recruiting now · Not applicable

Conditions studied: ADPKD (autosomal Dominant Polycystic Kidney Disease)

In brief

The purpose of this study is to generate clinical evidence and assess the feasibility of a shared decision-making (SDM) model for the selection of Tolvaptan in patients with ADPKD.

Key facts

Study ID

NCT06618638

Run by

Seoul National University Hospital

People needed

340

Starts

2024-10-21

Expected to finish

2026-09-30

Last updated by the study team

2024-11-07

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants between the age of 18 to 80
• Participants with a diagnosis with CKD stage 2 or 3
• Participants with a diagnosis with ADPKD classified as 1C, 1D, or 1E according to Mayo classification
• Participants with the ability to communicate and use digital devices
• Participants with no severe visual impairment and cognitive dysfunction

You may not qualify if…

• Participants who were previously exposured to tolvaptan
• Participants who are contraindicated to tolvaptan
• Participants who were judged ineligible by the investigator

Where it is running

• Seoul National University Hospital — Seoul, Republic of Korea, South Korea (enrolling)
• InjeUniversityBusanPaikHospital — Busan, South Korea
• Keimyung University Dongsan Medical Center — Daegu, South Korea
• Chonnam National University Hospital — Gwangju, South Korea
• Kangbuk Samsung Hospital — Seoul, South Korea
• Asan Medical Center — Seoul, South Korea
• Seoul National University Boramae Hospital — Seoul, South Korea
• Hallym University Kangnam Sacred Heart Hospital — Anyang-si, Gyeonggi-do, South Korea
• Korea University Guro Hospital — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.